DNA-hsp65 Vaccine as Therapeutic Strategy to Treat Experimental Chromoblastomycosis Caused by Fonsecaea Pedrosoi
| العنوان: | DNA-hsp65 Vaccine as Therapeutic Strategy to Treat Experimental Chromoblastomycosis Caused by Fonsecaea Pedrosoi |
|---|---|
| المؤلفون: | Márcio Souza Jerônimo, Florencio Figueiredo Cavalcante Neto, Isaque Medeiros Siqueira, Ana Camila Oliveira Souza, Karina Smidt Simon, Célio Lopes Silva, Maria Sueli Soares Felipe, Yanna Karla de Medeiros Nóbrega, Anamélia Lorenzetti Bocca, Alice Melo Ribeiro |
| المصدر: | Mycopathologia. 175:463-475 |
| بيانات النشر: | Springer Science and Business Media LLC, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Male, Cellular immunity, Antifungal Agents, Itraconazole, Veterinary (miscellaneous), Colony Count, Microbial, Biology, Applied Microbiology and Biotechnology, Microbiology, Bacterial Proteins, Amphotericin B, Vaccines, DNA, medicine, Animals, Immunologic Factors, Rats, Wistar, Mycosis, Chromoblastomycosis, Histocytochemistry, Chaperonin 60, medicine.disease, biology.organism_classification, Fonsecaea pedrosoi, Disease Models, Animal, Treatment Outcome, Immunology, Terbinafine, Agronomy and Crop Science, Fluconazole, medicine.drug |
| الوصف: | Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis, caused by several dimorphic, pigmented dematiaceous fungi. Patients with the disease are still considered a therapeutic challenge, mainly due to its recalcitrant nature. There is no "gold standard" treatment for this neglected mycosis, but rather there are several treatment options. Chemotherapy alternatives include 5-flucytosine, itraconazole, terbinafine, fluconazole, thiabendazole, ketoconazole and amphotericin B, although the healing of severe cases is still uncommon. However, several studies have reported the DNA vaccine to be promising in the treatment for fungal infections; this vaccine allows the host to restore depressed cellular immunity, minimizing the toxic effects from conventional antifungal therapies. This work was therefore carried out aiming to establish a suitable model for experimental CBM, suggesting also new therapies, including DNA-hsp65 vaccine. By analyzing the morphometrical and histopathological aspects and by quantifying the fungal burden, the results showed the establishment of a chronic, although transitory, experimental CBM model with lesions similar to those presented in humans. A treatment regimen using intralesional itraconazole or amphotericin B was effective in treating experimental CBM, as was a therapy using naked DNA-hsp65 vaccine. It has also been shown that chemotherapy associated with DNA-hsp65 vaccine is promising in the treatment for CBM. |
| تدمد: | 1573-0832 0301-486X |
| DOI: | 10.1007/s11046-012-9599-7 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97096c16d30d2292c4d0d4e8461a966b https://doi.org/10.1007/s11046-012-9599-7 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....97096c16d30d2292c4d0d4e8461a966b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15730832 0301486X |
|---|---|
| DOI: | 10.1007/s11046-012-9599-7 |